-Reuters
B of A Securities Maintains Buy on Catalent, Lowers Price Target to $125
B of A Securities analyst Derik De Bruin maintains Catalent (NYSE:CTLT) with a Buy and lowers the price target from $140 to $125.
Related Posts
Why Processa Pharmaceuticals Stock Is Soaring
Processa Pharmaceuticals shares are soaring Thursday after the company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine. Processa said the data obtained from the Phase 1b trial has been used to select two dosage regimens for the Phase 2 trial which will be in advanced or metastatic breast cancer given the FDA's agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.
Insight Earned all Seven Microsoft Solution Partner Designations in EMEA
Insight Enterprises (NASDAQ: NSIT), a Fortune 500 solutions integrator helping organisations accelerate their digital journey, today announced that it has achieved all possible Microsoft Solution Partner designations, including the rare seventh designation for Microsoft Cloud – only awarded to companies holding all other six d
Akerna Reports Halloween Weekend Cannabis Sales Total $249.6M
Akerna (NASDAQ:KERN), a leading enterprise software company and the developer of one of the most comprehensive technology infrastructures, ecosystems, and compliance engines powering the global cannabis industry, today